We found that addition of NPY dose-dependently inhibited cisplatin-induced AKI by reducing the severity of tubular necrosis and serum levels of creatinine, with an optimal dose at 50 μg/kg/day (Figure 4 a, c, d). The gene discussed is NPY; the disease is acute kidney injury.